{"entity":{"id":"idea-lung-uk-screening-testing-and-access-gaps","kind":"idea","name":"Close the United Kingdom lung cancer gaps the UK page names: screening rollout, diagnostic pathway, molecular testing and drug access","aka":[],"tldr":"A placeholder for the United Kingdom-specific gaps: where the Targeted Lung Health Check programme has reached and who it misses, how long the pathway takes from scan to treatment, how fast a tumour is genotyped, and which of the drugs on this roadmap are funded.","summary":"This record exists so the roadmap can point at the United Kingdom delivery gaps without duplicating them. Programme coverage and uptake by deprivation, the diagnostic interval from abnormal scan to treatment decision, thoracic surgery and radiotherapy capacity, genomic laboratory hub turnaround, which alterations the national test directory covers, and the NICE and Cancer Drugs Fund status of osimertinib, alectinib, lorlatinib, sotorasib, durvalumab and tarlatamab all belong to the UK and NHS page for lung cancer, which owns those numbers.\n\nWhen the UK page names its gaps, this record takes their titles and its hypothesis and test are rewritten from them. Until then it holds the link between the evidence roadmap and the delivery question, and carries no figures of its own.","asOf":"2026-09-25","links":[],"tags":["lung-evidence"],"related":["idea-prev-mobile-lung-screening-deprived-areas","diagnostics-roadmap","lung-cancer-evidence-roadmap"],"cancers":["lung-cancer","nsclc","sclc"],"sections":["early-detection","diagnostics"],"technologies":["ngs","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["nice"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-care-fragmentation","b-workforce","b-global-access","b-drug-pricing"],"keyPapers":["paper-uspstf-lung-cancer-screening-jama-2021","paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013","paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"To be written from the gaps the United Kingdom and NHS page for lung cancer names: a placeholder held by the evidence file so the roadmap has somewhere to point.","rationale":"The evidence files own the published trials and the roadmap; the UK file owns programme coverage, capacity, testing turnaround and guideline positions. Every targeted and perioperative result on this roadmap depends on a test happening fast enough to act on and a drug being funded, and those are national questions with national answers. Keeping the delivery gap as a named placeholder rather than as an unsourced claim means the roadmap stays honest about what it has read.","test":"To be written from the United Kingdom and NHS page for lung cancer once its gaps are named.","maturity":"speculative","actor":"policy","cost":"medium","horizonYears":5},"route":"/ideas/idea-lung-uk-screening-testing-and-access-gaps/","neighbours":{"idea":[{"id":"idea-prev-mobile-lung-screening-deprived-areas","kind":"idea","name":"Take lung screening scanners to supermarket car parks in the poorest areas","route":"/ideas/idea-prev-mobile-lung-screening-deprived-areas/"}],"roadmap":[{"id":"diagnostics-roadmap","kind":"roadmap","name":"Diagnostics roadmap: stains → gene panels → blood tests that decide treatment","route":"/roadmaps/diagnostics-roadmap/"},{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/"}],"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"term":[{"id":"ngs","kind":"term","name":"Next-generation sequencing (NGS)","route":"/terms/ngs/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"institution":[{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","route":"/institutions/nice/"}],"bottleneck":[{"id":"b-care-fragmentation","kind":"bottleneck","name":"Fragmented care and guideline gaps","route":"/bottlenecks/b-care-fragmentation/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-workforce","kind":"bottleneck","name":"Not enough oncologists, nurses, pathologists, physicists","route":"/bottlenecks/b-workforce/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"}],"paper":[{"id":"paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011","kind":"paper","name":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","route":"/key-papers/paper-sequist-genotypic-histological-evolution-egfr-resistance-sci-transl-med-2011/"},{"id":"paper-uspstf-lung-cancer-screening-jama-2021","kind":"paper","name":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","route":"/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/"},{"id":"paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013","kind":"paper","name":"Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis","route":"/key-papers/paper-forrest-socioeconomic-inequalities-lung-cancer-treatment-plos-med-2013/"}]}}